Viking Therapeutics (VKTX) Tops Q4 EPS by 4c
Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18).
At December 31, 2017, Viking held cash, cash equivalents and investments totaling $20.6 million. In February 2018, Viking sold an aggregate of 12,650,000 shares of its common stock resulting in gross proceeds of $63.3 million before deducting underwriting discounts and commissions and other offering expenses. As of February 28, 2018, Viking had 50,898,802 shares of common stock outstanding.
For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.